PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33078278-4	2021	Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells.	Idarubicin	84-94	CD34 molecule	Homo sapiens	134-138	
33078278-4	2021	Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells.	Idarubicin	84-94	CD34 molecule	Homo sapiens	159-163	
33078278-4	2021	Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells.	Idarubicin	84-94	CD34 molecule	Homo sapiens	159-163	
33078278-4	2021	Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells.	Idarubicin	96-99	CD34 molecule	Homo sapiens	134-138	
33078278-4	2021	Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells.	Idarubicin	96-99	CD34 molecule	Homo sapiens	159-163	
33078278-4	2021	Our results showed that low-dose Triptolide (TPL) enhanced the anti-AML activity of Idarubicin (IDA) in vitro against LSC-like cells (CD34 + CD38- KG1alphaand CD34 + CD38- kasumi-1 cells) and CD34+ primary AML cells, while sparing normal cells.	Idarubicin	96-99	CD34 molecule	Homo sapiens	159-163